Using Knowledge Graphs to Drive Drug Discoverynews2022-04-21T14:05:25+00:00April 21st, 2022|FierceBiotech|
Who’s who of biopharma execs backs tiny Dutch startup’s bid to treat rare diseasenews2022-04-21T12:14:44+00:00April 21st, 2022|FierceBiotech|
Déjà vu: Ampio’s stock sinks as FDA rejects COVID-19-ravaged osteoarthritis trialnews2022-04-21T10:10:49+00:00April 21st, 2022|FierceBiotech|
Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnershipnews2022-04-21T01:51:15+00:00April 21st, 2022|FierceBiotech|
Novavax touts early data for flu-COVID combo vaccine as FDA decision looms for single shotnews2022-04-20T18:12:41+00:00April 20th, 2022|FierceBiotech|
UPDATE: Aptinyx pauses phase 2 trial of higher dose PTSD med to save cashnews2022-04-20T15:30:17+00:00April 20th, 2022|FierceBiotech|
Windtree’s phase 2 shock med rapidly raises blood pressure—and share pricenews2022-04-20T13:34:53+00:00April 20th, 2022|FierceBiotech|
Arcturus’ stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3news2022-04-20T12:20:30+00:00April 20th, 2022|FierceBiotech|
AbbVie shreds alpha-synuclein Parkinson’s pact on cusp of phase 2, thinning field led by Rochenews2022-04-20T10:55:05+00:00April 20th, 2022|FierceBiotech|
Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapiesnews2022-04-20T04:30:36+00:00April 20th, 2022|FierceBiotech|
